Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Variants & evidence
522 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ABL1 E279K + ABL1 Fusion1 | |||||||
| Dasatinib | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4544In an in vitro study, Ba/F3 cell line stably expressing the E279K mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to dasatinib treatment (IC50: 3nM vs. IC50: 1… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| ABL1 E292L + ABL1 Fusion1 | |||||||
| Axitinib | Predictive | D | Does Not Support Resistance | 2 | accepted | EID7773In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| ABL1 E292V + ABL1 Fusion2 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4474In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| Nilotinib | Predictive | D | Supports Resistance | 2 | accepted | EID2853In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The E292V mutation in the ABL1 portion of the BCR-ABL1 fu… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| ABL1 E355G + ABL1 Fusion10 | |||||||
| Bosutinib | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4400In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| Dasatinib | Predictive | B | Does Not Support Resistance | 2 | accepted | EID4403This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4404Prior to dasatinib treatment, three imatinib-resistant patients with chronic myeloid leukemia had the BCR-ABL1 fusion with the E355G secondary variant in one or more bacterial clones. Clones were gene… | |
| ABL1 E450Q + ABL1 Fusion1 | |||||||
| Dasatinib | Predictive | C | Does Not Support Resistance | 4 | accepted | EID7942Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with E450Q/M351T and E450Q variants in 1/10 and 9/10 clones, respect… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| ABL1 E450V + ABL1 Fusion2 | |||||||
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4563In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4564In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 E453A + ABL1 Fusion2 | |||||||
| Bosutinib | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4567This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID6980In a study of 39 chronic phase CML patients with BCR-ABL variants, E453A was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| ABL1 E453K + ABL1 Fusion2 | |||||||
| Bosutinib | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4565In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4566In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 E453Q + ABL1 Fusion1 | |||||||
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4486In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| ABL1 E459K + ABL1 Fusion4 | |||||||
| Dasatinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6310This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 1 | accepted | EID7031In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 2 | accepted | EID8092In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… | |
| ABL1 E98G + ABL1 Fusion2 | |||||||
| Dasatinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4711Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the E98G secondary variant in 11/11 bacterial clones generated … (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 1 | accepted | EID7822One chronic myeloid leukemia patient in chronic phase had a complete best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA later revealed th… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| ABL1 F311I + ABL1 Fusion3 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID4477In an in vitro study, pro-B Ba/F3 cell line expressing F311I mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 935.6nM),… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4478In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4479In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… | |
| ABL1 F311L + ABL1 Fusion4 | |||||||
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4546In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4547In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4548In an in vitro study, a Ba/F3 cell line expressing a F311L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (1.3 nmol/L vs. 0.8 nmol/L… | |
| ABL1 F317C + ABL1 Fusion1 | |||||||
| Dasatinib | Predictive | D | Supports Resistance | 2 | accepted | EID6250In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| ABL1 F317I + ABL1 Fusion2 | |||||||
| Dasatinib | Predictive | D | Supports Resistance | 2 | accepted | EID6251In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 1 | accepted | EID6217In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasat… (full text at CIViC) PMID 15705718 · Burgess et al., 2005 · Open in CIViC | civic |
| ABL1 F317L + ABL1 Fusion12 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID4390In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID4391In an in vitro study, a pro-B Ba/F3 cell line expressing F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 1170nM)… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4381In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… | |
Data updated 18 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 16775234 · Talpaz et al., 2006 · Open in CIViC
| civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4401In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the AB… (full text at CIViC) PMID 19487385 · Apperley et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4402In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4405In an in vitro study, a Ba/F3 cell line stably expressing the E355G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as compa… (full text at CIViC) PMID 15256671 · Shah et al., 2004 · Open in CIViC | civic |
| Imatinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID2664In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A CP patient had complete cytogenetic response u… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Resistance | 3 | accepted | EID8090In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An acute-phase patient achieved complete hematol… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID7036In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had E355G mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID6255In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
PMID 12623848 · Branford et al., 2003 · Open in CIViC
| civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID7046In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had E459K mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
PMID 19779040 · Müller et al., 2009 · Open in CIViC
| civic |
PMID 15930265 · O'Hare et al., 2005 · Open in CIViC
| civic |
| Imatinib Mesylate + NilotinibCombination | Predictive | D | Supports Resistance | 2 | accepted | EID6238In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
PMID 21865346 · Cortes et al., 2011 · Open in CIViC
| civic |
| 〃 | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID4382This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | submitted | EID4380In an in vitro study, a Ba/F3 murine cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | B | Supports Resistance | 5 | accepted | EID637BCR-ABL F317L has been shown to confer resistance to dasatinib in patients with CML. PMID 18818391 · Jabbour et al., 2008 · Open in CIViC | civic |
| 〃 | Predictive | B | Supports Resistance | 3 | accepted | EID6309This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase) patients with mutations in the BCR-ABL gene fusion kinase domain from t… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Resistance | 2 | submitted | EID4384In a retrospective study of 45 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABLfusion positive (Ph+) chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia (ALL) patients, patie… (full text at CIViC) PMID 17339191 · Soverini et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Resistance | 2 | submitted | EID4385In a retrospective study (of phase 3 clinical trial NCT00481247) of 363 Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia patients in chronic phase, a patient with the F317I mutation in … (full text at CIViC) PMID 26118315 · Hughes et al., 2015 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID7030In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 3 | accepted | EID6215In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasat… (full text at CIViC) PMID 15705718 · Burgess et al., 2005 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | submitted | EID4383In an in vitro study, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 8… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |